TirzepatideTirzepatide for Chronic Kidney Failure with Diabetes or Obesity

This study aims to explore the safety and effectiveness of a medication called tirzepatide (also known as Spartina) for people with chronic kidney failure who are not yet on dialysis. The focus is on patients who also have diabetes or obesity, specifically those with a body mass index (BMI) over 27. By studying this group, researchers hope to find better treatment options that can help manage kidney function and related health issues. This trial is important because it seeks to address the challenges faced by patients with chronic kidney disease, including those related to weight and blood sugar management. Participants in this trial will visit Labafinezhad Hospital in Tehran, Iran, where they will receive tirzepatide therapy. The study will monitor changes in various health markers such as weight, BMI, triglycerides, insulin needs, and blood sugar levels to determine how well the medication works. Safety will also be evaluated by checking thyroid and liver functions, as well as other relevant health indicators. The study will collect data at the beginning, and then after one and three months to assess both the efficacy and safety of the treatment. The goal is to better understand the potential benefits and risks of using tirzepatide in this patient population.